Early completion of the WHI study and subsequent publicity about these previously unvalued risks led to a decrease in CHRT recipes. WHI results were used by BHT prescribers to promote bio-identical hormones as safer than regulated preparations by the FDA despite lack of evidence; according to the FDA, the results of the study apply to all estrogens. Since then, BHT has been strongly promoted as a natural alternative with fewer risks than CHRT, although there is no evidence to support this claim. BHT professionals recommend composite products because of their claim that they better mimic the composition and proportion of circulating hormones in a woman’s body than commercially manufactured products. Bioidene hormone replacement therapy, also known as bioidene hormone therapy or natural hormone therapy, is the use of hormones that are molecularly identical to endogenous hormones in hormone replacement therapy.
An overview of clinical studies on the use of bio-identical progesterone showed that it was not effective in treating vasomotor symptoms of menopause, but had mild and self-limiting side effects. While they may be safer for women who are allergic to an additive in commercially available hormones, tailor-made hormone therapy carries risks similar to bio-identical hormone therapy. The use of correctly dosed bio-identical hormones has been shown to reduce and eliminate many of the risks of hormone replacement therapy. In addition, specific treatments help minimize side effects, especially when taking into account patient compliance and frequency of use.
There have been no clinical studies directly comparing the effectiveness or efficacy of bioidentical versus non-bioidenthic compounds. DHEA is an androgen precursor that does not have FDA and Health Canada approval for use in women and is not available as a pharmaceutical preparation in Canada; sold as a freely available drug or incorporated in compound preparations in the United States. In the body it can be converted into testosterone and then estrogen; There are no consistent scientific findings or safety information to support its use. In premenopausal women, most of the body-produced estrogen is estradiol, while in postmenopausal women, estrogen is the type of estrogen most present; however, the body can convert one type of estrogen into another to some degree.
Derzko concluded that there was weak preliminary evidence that bio-identical hormones can pose equal risks to conventional HRT; however, there was no data to support the use of compounds. Derzko advised to follow fact-based medications and raised concerns about BHT by many medical organizations: requirements for compositional monitoring, black box alerts Hormone Replacement Therapy Near Me for all bio-identical products and establishing a mandatory register of side effects. There is no definition whatsoever for the term “bioid hormone replacement therapy”; It is generally used to refer to 17β-estradiol, but other uses include vegetable estrogen products or compounds that combine estradiol with estriol and sometimes with estrone.
Personalized bio-identical hormones are often advertised as a safer, more effective, more natural and individualized alternative to conventional hormone therapy. However, these claims are not supported by large-scale, well-designed investigations. In addition, the FDA’s lack of monitoring of compound hormones creates additional risks related to the purity and safety of custom composite bio-identical hormones. These additional hormones have not been properly tested and are therefore not included in an FDA approved product